Retained Blood Syndrome Role in Complicating LVAD Recovery Discussed at International Heart Transplant Conference

April 29, 2016, 10:47 pm

≫ Next: Quality Improvement Program to Minimize Complications from Retained Blood in Heart Surgery Patients

≪ Previous: New Data Indicates Patients with Retained Blood are 75% More Likely to Suffer from Hospital Acquired Infections After Heart Surgery

$

0

0

— ClearFlow Executives Comment on Possible Solutions to Retained Blood Syndrome for  Challenging Patient Population– Anaheim, CA – April 28, 2016—Cardiac surgery investigators presented data revealing the role retained blood plays in complications after left ventricular assist device (LVAD) implantation this week at the International Society for Heart & Lung Transplantation 2016 Annual Meeting in Washington, DC. All patients recovering from LVAD implantation require chest tubes to drain shed blood around the heart and lungs in early recovery. If these chest tubes clog, Retained Blood Syndrome (RBS) may occur. Yesterday, Mayo Clinic heart surgeon Simon Maltais, MD, Ph.D, presented data from 252 patients undergoing VAD implantation. Results revealed that more

The post Retained Blood Syndrome Role in Complicating LVAD Recovery Discussed at International Heart Transplant Conference appeared first on ClearFlow.

---

Quality Improvement Program to Minimize Complications from Retained Blood in Heart Surgery Patients

May 10, 2016, 10:55 am

≫ Next: Leading Surgeons Convene to Discuss the Problem of Retained Blood After Heart Surgery

≪ Previous: Retained Blood Syndrome Role in Complicating LVAD Recovery Discussed at International Heart Transplant Conference

$

0

0

Anaheim, CA — (May 10, 2016) — ClearFlow, Inc., a California-based company that develops technology to maximize post-operative blood evacuation after cardiac surgery, has signed an agreement with Mayo Clinic in Rochester, MN for research on a Continuous Quality Improvement (CQI) program for patients recovering from heart surgery. Simon Maltais, M.D., Mayo Clinic Associate Professor, Division of Cardiovascular Surgery, is the Principal Investigator. Originally implemented in Japanese manufacturing companies in the 1950’s, CQI programs have been adopted by many industries and are an important tool now being used in leading hospitals to improve the quality and safety of patient care in the healthcare setting. “Recent studies have demonstrated that up

The post Quality Improvement Program to Minimize Complications from Retained Blood in Heart Surgery Patients appeared first on ClearFlow.

Leading Surgeons Convene to Discuss the Problem of Retained Blood After Heart Surgery

June 15, 2016, 5:39 pm

≫ Next: Newly Published Study in Journal of Thoracic and Cardiovascular Surgery Confirms Heavy Toll of Retained Blood Syndrome on Post-Surgery Outcomes and Hospital Resource Utilization

≪ Previous: Quality Improvement Program to Minimize Complications from Retained Blood in Heart Surgery Patients

$

0

0

–ClearFlow Hosts Panel of Thought Leaders in Montreal– Montreal, Canada — June 16, 2016 — A panel of distinguished heart surgeons from leading cardiac centers shared their experiences and strategies to optimize patient recovery after cardiothoracic surgery at a panel discussion in Montreal yesterday. Of emphasis was the ongoing challenge of high complication rates for patients who have inadequate postoperative blood evacuation, known as Retained Blood Syndrome (RBS), and how this impacts the development of Postoperative Atrial Fibrillation (POAF) after cardiac surgery. ClearFlow, Inc., a medical device company based in Anaheim, California, hosted the evening Symposium in Montreal. ClearFlow is the manufacturer of the innovative PleuraFlow® Active Clearance Technology® System –

The post Leading Surgeons Convene to Discuss the Problem of Retained Blood After Heart Surgery appeared first on ClearFlow.

Newly Published Study in Journal of Thoracic and Cardiovascular Surgery Confirms Heavy Toll of Retained Blood Syndrome on Post-Surgery Outcomes and Hospital Resource Utilization

June 28, 2016, 7:00 am

≫ Next: ClearFlow Named MM&M Award Finalist for ‘Best Branded Website for Healthcare Professionals’

≪ Previous: Leading Surgeons Convene to Discuss the Problem of Retained Blood After Heart Surgery

$

0

0

–ClearFlow Technology Offers Solution– Anaheim, CA – June 28, 2016—ClearFlow Inc., a medical device company based in Anaheim, California, has announced the publication of another peer reviewed study in a leading cardiovascular surgery journal emphasizing the importance of preventing Retained Blood Syndrome (RBS). The Journal of Thoracic and Cardiovascular Surgery has published a peer-reviewed study from cardiac anesthesia and surgical investigators in Berlin detailing the heavy toll unevacuated retained blood plays on patients recovering after heart surgery.  The investigators from Charité – Universitätsmedizin Berlin’s Department of Anesthesiology and Intensive Care Medicine and Cardiac Surgery Department evaluated clinical data  on nearly 7,000 patients who underwent heart surgery and examined the outcomes

The post Newly Published Study in Journal of Thoracic and Cardiovascular Surgery Confirms Heavy Toll of Retained Blood Syndrome on Post-Surgery Outcomes and Hospital Resource Utilization appeared first on ClearFlow.

ClearFlow Named MM&M Award Finalist for ‘Best Branded Website for Healthcare Professionals’

July 14, 2016, 9:28 pm

≫ Next: ClearFlow Launches FDA-Cleared PleuraFlow System for Pediatric Cardiothoracic Surgery

≪ Previous: Newly Published Study in Journal of Thoracic and Cardiovascular Surgery Confirms Heavy Toll of Retained Blood Syndrome on Post-Surgery Outcomes and Hospital Resource Utilization

$

0

0

Anaheim, CA – July 14, 2016—ClearFlow Inc., a medical device company based in Anaheim, California, has been named a finalist for this year’s Medical Marketing & Media (MM&M) Awards. MM&M, the premier business publication serving the healthcare industry for nearly 50 years, named ClearFlow’s interactive website among the five finalists in the category of Best Branded Website for Healthcare Professionals.’ Winners will be announced at the MM&M Awards ceremony on October 6, at a black-tie dinner at Cipriani Wall Street in Manhattan. The finalists survived a gauntlet of two rounds of judging performed by about 125 healthcare marketers. ClearFlow’s site, with its clean design and physician-friendly resources and blog, was

The post ClearFlow Named MM&M Award Finalist for ‘Best Branded Website for Healthcare Professionals’ appeared first on ClearFlow.

ClearFlow Launches FDA-Cleared PleuraFlow System for Pediatric Cardiothoracic Surgery

July 26, 2016, 9:25 am

≫ Next: Clinical and Economic Benefits of Maintaining Chest Tube Patency Discussed at Cardiovascular-Thoracic (CVT) Critical Care Conference

≪ Previous: ClearFlow Named MM&M Award Finalist for ‘Best Branded Website for Healthcare Professionals’

$

0

0

Anaheim, CA – July 26, 2016 — ClearFlow, Inc., a medical device company based in Anaheim, California, has announced that its PleuraFlow® Active Clearance Technology® is now available for the treatment of pediatric cardiothoracic surgery patients.  After receiving clearance from the United States Food & Drug Administration (FDA) earlier this year for expanded Indications for Use with the company’s patented technology, ClearFlow developed a new model of the PleuraFlow product for the pediatric market. All patients undergoing heart surgery have some degree of bleeding, and thus, all patients require chest tubes to evacuate shed blood from around the heart and lungs in the early hours after surgery. The problem is

The post ClearFlow Launches FDA-Cleared PleuraFlow System for Pediatric Cardiothoracic Surgery appeared first on ClearFlow.

Clinical and Economic Benefits of Maintaining Chest Tube Patency Discussed at Cardiovascular-Thoracic (CVT) Critical Care Conference

September 20, 2016, 10:14 am

≫ Next: ClearFlow Opens New Distribution Center to Service European Market

≪ Previous: ClearFlow Launches FDA-Cleared PleuraFlow System for Pediatric Cardiothoracic Surgery

$

0

0

ClearFlow Participates in Clinical Panel Presentations at Critical Care Conference Washington, DC – September 20, 2016—ClearFlow Inc., a medical device company based in Anaheim, CA, participated in a series of panel presentations related to the clinical and economic benefits of maintaining chest tube patency following cardiothoracic surgery last Friday at a session sponsored during the Cardiovascular-Thoracic (CVT) Critical Care Conference in Washington DC. Clinical cardiac surgery intensive care leaders from around the world gathered at the conference, organized by the Foundation for the Advancement of CardioThoracic Surgical Care (FACTS-Care) in Washington, DC. CVT Critical Care Conference is one of the premier settings for cardiac critical care exchange of ideas. Specialists

The post Clinical and Economic Benefits of Maintaining Chest Tube Patency Discussed at Cardiovascular-Thoracic (CVT) Critical Care Conference appeared first on ClearFlow.

ClearFlow Opens New Distribution Center to Service European Market

September 28, 2016, 7:11 am

≫ Next: Active Clearance of Chest Tubes Reduces Bleeding Complications After Left Ventricular Assist Device Implantation for Heart Failure

≪ Previous: Clinical and Economic Benefits of Maintaining Chest Tube Patency Discussed at Cardiovascular-Thoracic (CVT) Critical Care Conference

$

0

0

Elsloo, THE NETHERLANDS – September 28, 2016 — ClearFlow, Inc., a medical device company headquartered in Anaheim, California and with a European office in Amsterdam, has announced the opening of its new dedicated European Service Center near Maastricht, the Netherlands. ClearFlow is the maker of the PleuraFlow® Active Clearance Technology® System, which proactively prevents or minimizes chest tube clogging. A chest tube that is occluded can lead to retained blood around the heart and lungs, which in turn leads to an increase in likelihood of complications and extended hospital stays. The PleuraFlow System is approved for use in the U.S., Europe, Australia, Brazil, and Canada, and has either cleared or

The post ClearFlow Opens New Distribution Center to Service European Market appeared first on ClearFlow.

---

Active Clearance of Chest Tubes Reduces Bleeding Complications After Left Ventricular Assist Device Implantation for Heart Failure

November 15, 2016, 3:30 pm

≫ Next: New Study Reveals that All Patients May be at Risk for Retained Blood after Heart Surgery

≪ Previous: ClearFlow Opens New Distribution Center to Service European Market

$

0

0

ClearFlow Announces New Clinical Study with Positive Results for the PleuraFlow System Anaheim, CA – November 15, 2016. ClearFlow, Inc., a medical device company based in Anaheim, California has announced the publication of positive results in a clinical trial evaluating the PleuraFlow® Active Clearance Technology® System. Data indicating a marked reduction in Retained Blood Syndrome (RBS) among patients recovering from implantation of left ventricular assist devices (LVAD) was published in the November/December 2016 edition of the American Society of Artificial Internal Organs (ASAIO) Journal (Vol. 62, Issue 66, p. 704-709). Data from the peer-reviewed paper, titled “Active Clearance of Chest Tubes Reduces Re-exploration for Bleeding After Ventricular Assist Device Implantation”

The post Active Clearance of Chest Tubes Reduces Bleeding Complications After Left Ventricular Assist Device Implantation for Heart Failure appeared first on ClearFlow.

New Study Reveals that All Patients May be at Risk for Retained Blood after Heart Surgery

January 31, 2017, 2:21 pm

≫ Next: ClearFlow Receives Frost & Sullivan ‘New Product Innovation’ Award for PleuraFlow Technology

≪ Previous: Active Clearance of Chest Tubes Reduces Bleeding Complications After Left Ventricular Assist Device Implantation for Heart Failure

$

0

0

— ClearFlow Executives Comment on Need for New Protocols —  Anaheim, CA – January 31, 2017—Clinical study results presented at the Society of Critical Care Medicine (SCCM) 46th Annual Critical Care Congress in Honolulu last week suggest that all heart surgery patients are at risk for Retained Blood Syndrome, not just high-risk patients, as previously assumed. All patients having heart surgery are required to have drainage catheters to remove shed blood from around the heart and lungs in the early hours of recovery following surgery.  Evidence suggests that these drainage catheters, or chest tubes, have a high failure rate due to clogging, leading to what is known as Retained Blood

The post New Study Reveals that All Patients May be at Risk for Retained Blood after Heart Surgery appeared first on ClearFlow.

ClearFlow Receives Frost & Sullivan ‘New Product Innovation’ Award for PleuraFlow Technology

April 18, 2017, 9:13 am

≫ Next: ClearFlow, Inc. Receives FDA Clearance for FlowGlide™ Technology for Cardiac Surgery Patients

≪ Previous: New Study Reveals that All Patients May be at Risk for Retained Blood after Heart Surgery

$

0

0

Anaheim, CA – April 18, 2017—ClearFlow Inc., a medical device company based in Anaheim, California, has received the prestigious 2017 Global Frost & Sullivan Award for New Product Innovation. The award was presented to ClearFlow for its development of the PleuraFlow® Active Clearance Technology® (ACT®) System, which has been clinically shown to reduce the occurrence of complications after cardiac surgery. Evidence suggests that chest tubes which are used for drainage after cardiac surgery have a high failure rate due to clogging. If the extra blood isn’t removed from inside the chest cavity after surgery, patients may require additional procedures which are known as Retained Blood Syndrome (RBS). Multiple studies have shown

The post ClearFlow Receives Frost & Sullivan ‘New Product Innovation’ Award for PleuraFlow Technology appeared first on ClearFlow.

ClearFlow, Inc. Receives FDA Clearance for FlowGlide™ Technology for Cardiac Surgery Patients

June 23, 2017, 1:20 am

≫ Next: ClearFlow Expands Distribution of PleuraFlow System for Pediatric Cardiothoracic Surgery

≪ Previous: ClearFlow Receives Frost & Sullivan ‘New Product Innovation’ Award for PleuraFlow Technology

$

0

0

Anaheim, CA – June 20, 2017 — ClearFlow, Inc., a medical device company based in Anaheim, California, announced today that the United States Food & Drug Administration (FDA) has granted 510[k] clearance for the company’s proprietary FlowGlide™ Active Clearance Technology® System. The FlowGlide™ System is the next generation of ClearFlow’s Active Clearance Technology that prevents or reduces chest drains from occluding with clot, which can lead to retained blood around the heart and lungs. The composite of drainage-related complications that are detrimental to outcomes after cardiothoracic surgery and that may require early or late intervention to remediate is known as Retained Blood Syndrome (RBS). These clinical complications have significant economic

The post ClearFlow, Inc. Receives FDA Clearance for FlowGlide™ Technology for Cardiac Surgery Patients appeared first on ClearFlow.

ClearFlow Expands Distribution of PleuraFlow System for Pediatric Cardiothoracic Surgery

July 19, 2017, 9:32 pm

≫ Next: ClearFlow, Inc. Announces Positive US Clinical Trial Results

≪ Previous: ClearFlow, Inc. Receives FDA Clearance for FlowGlide™ Technology for Cardiac Surgery Patients

$

0

0

Anaheim, CA – July 19, 2017 — ClearFlow, Inc., a medical device company based in Anaheim, California, has announced a full market release for the 20Fr SEDL version of the PleuraFlow® Active Clearance Technology® System for the treatment of pediatric cardiothoracic surgery patients. The SEDL refers to the “shorter effective drainage length”, which facilitates placement of the PleuraFlow chest tube in the smaller chests of pediatric patients. ClearFlow received clearance from the United States Food & Drug Administration (FDA) as well as the CE mark last year for expanded Indications for Use with the company’s patented technology and developed a new model of the PleuraFlow product for the pediatric market.

The post ClearFlow Expands Distribution of PleuraFlow System for Pediatric Cardiothoracic Surgery appeared first on ClearFlow.

ClearFlow, Inc. Announces Positive US Clinical Trial Results

August 21, 2017, 9:39 pm

≫ Next: Newly Published Peer Reviewed Study Reveals Benefits of ClearFlow’s PleuraFlow ACT System

≪ Previous: ClearFlow Expands Distribution of PleuraFlow System for Pediatric Cardiothoracic Surgery

$

0

0

Reduction of Hospital Complications and Resource Utilization after Heart Surgery Demonstrated with Use of the PleuraFlow® ACT® System. New York City, NY – August 21, 2017 — ClearFlow, Inc., a medical device company based in Anaheim, California, announced today that positive clinical trial results were presented at the International Coronary Congress (ICC) 2017 annual meeting on August 18th, 2017 in New York City, NY. The findings were presented by the study principal investigator, Dr. Yvon Baribeau, of Catholic Medical Center in Manchester, New Hampshire, in a presentation titled “Active Clearance of Chest Drains Reduces Retained Blood and ICU Resources after Off-Pump Coronary Artery Bypass Surgery”. This data stems from a

The post ClearFlow, Inc. Announces Positive US Clinical Trial Results appeared first on ClearFlow.

Newly Published Peer Reviewed Study Reveals Benefits of ClearFlow’s PleuraFlow ACT System

September 27, 2017, 8:23 am

≫ Next: Studies Recognizing the Importance of Limiting Retained Blood to Prevent Postoperative Atrial Fibrillation Featured on January Cover of Annals of Thoracic Surgery

≪ Previous: ClearFlow, Inc. Announces Positive US Clinical Trial Results

$

0

0

–Study Supports Previously Published Data on Reduction of Postoperative Atrial Fibrillation After Heart Surgery Among Patients Treated with PleuraFlow Active Clearance Technology– Anaheim, CA – September 27, 2017—ClearFlow Inc., a medical device company based in Anaheim, California, has announced the publication of significantly positive results in a study evaluating the company’s PleuraFlow® Active Clearance Technology® System. Data from a peer-reviewed clinical study indicating a marked reduction in Postoperative Atrial Fibrillation (POAF) among patients with active clearance of chest tubes after heart surgery was published in the August edition of the Journal of Thoracic and Cardiovascular Surgery. The study is titled “Examining the impact of active clearance of chest drainage catheters

The post Newly Published Peer Reviewed Study Reveals Benefits of ClearFlow’s PleuraFlow ACT System appeared first on ClearFlow.

---

Studies Recognizing the Importance of Limiting Retained Blood to Prevent Postoperative Atrial Fibrillation Featured on January Cover of Annals of Thoracic Surgery

February 1, 2018, 9:03 am

≫ Next: ClearFlow Reports: ERAS Cardiac Surgery Recommends Active Tube Clearance Methodology in Consensus Statement Presented at the 98th Annual Meeting of The American Association for Thoracic Surgeons

≪ Previous: Newly Published Peer Reviewed Study Reveals Benefits of ClearFlow’s PleuraFlow ACT System

$

0

0

–ClearFlow spokespeople cite review article as latest piece of mounting evidence pertaining to urgent need for managing retained blood after surgery– Anaheim, CA – February 1, 2018—ClearFlow Inc., a medical device company based in Anaheim, California, has announced that the cover of the January, 2018 issue of The Annals of Thoracic Surgery features a review article that elucidates the biological mechanisms by which retained shed mediastinal blood can trigger postoperative atrial fibrillation (POAF) in susceptible individuals as well as how this could represent a new target for prevention of POAF. The article can be viewed online here: http://www.annalsthoracicsurgery.org/article/S0003-4975(17)31095-0/fulltext The article’s author group is comprised of key opinion leaders on the

The post Studies Recognizing the Importance of Limiting Retained Blood to Prevent Postoperative Atrial Fibrillation Featured on January Cover of Annals of Thoracic Surgery appeared first on ClearFlow.

ClearFlow Reports: ERAS Cardiac Surgery Recommends Active Tube Clearance Methodology in Consensus Statement Presented at the 98th Annual Meeting of The American Association for Thoracic Surgeons

May 2, 2018, 11:24 am

≫ Next: ClearFlow Announces Additional Positive US Clinical Trial Results at the 2018 NTI Critical Care Exposition

≪ Previous: Studies Recognizing the Importance of Limiting Retained Blood to Prevent Postoperative Atrial Fibrillation Featured on January Cover of Annals of Thoracic Surgery

$

0

0

  San Diego, California – May 2, 2018 – ClearFlow Inc. has announced that an international society of leading heart surgeons known as ERAS® Cardiac Surgery presented evidenced-based expert consensus statements at the 98th annual meeting of the American Association for Thoracic Surgeons on April 28, 2018. Amongst key recommendations to promote enhanced patient outcomes after cardiac surgery is the use of Active Clearance techniques to maintain chest tube patency.  The PleuraFlow® ACT® System is the only FDA cleared device with the indication to prevent or minimize retained blood in patients recovering from heart surgery. The PleuraFlow ACT System is indicated for use during cardiothoracic surgical procedures and chest trauma.

The post ClearFlow Reports: ERAS Cardiac Surgery Recommends Active Tube Clearance Methodology in Consensus Statement Presented at the 98th Annual Meeting of The American Association for Thoracic Surgeons appeared first on ClearFlow.

ClearFlow Announces Additional Positive US Clinical Trial Results at the 2018 NTI Critical Care Exposition

May 29, 2018, 3:21 pm

≫ Next: Reduction in Bleeding Complications After LVAD Implantation

≪ Previous: ClearFlow Reports: ERAS Cardiac Surgery Recommends Active Tube Clearance Methodology in Consensus Statement Presented at the 98th Annual Meeting of The American Association for Thoracic Surgeons

$

0

0

ClearFlow Announces Additional Positive US Clinical Trial Results at the 2018 NTI Critical Care Exposition Reduction of Hospital Complications and Resource Utilization after Heart Surgery Demonstrated with Use of the PleuraFlow® ACT® System.  Boston, MA – May 29th, 2018 — ClearFlow, Inc., a medical device company based in Anaheim, California, has announced that positive clinical trial results were presented at the National Teaching Institute (NTI) & Critical Care Exposition 2018 annual meeting on May 23rd, 2018 in Boston, MA.  The findings were presented by the study principal investigator, Dr. Yvon Baribeau, of Catholic Medical Center in Manchester, New Hampshire, in a presentation titled “Active Clearance of Chest Drains Reduces Pleural

The post ClearFlow Announces Additional Positive US Clinical Trial Results at the 2018 NTI Critical Care Exposition appeared first on ClearFlow.

Reduction in Bleeding Complications After LVAD Implantation

November 15, 2016, 3:30 pm

≫ Next: New Study Reveals that All Patients May be at Risk for Retained Blood after Heart Surgery

≪ Previous: ClearFlow Announces Additional Positive US Clinical Trial Results at the 2018 NTI Critical Care Exposition

$

0

0

ClearFlow Announces New Clinical Study with Positive Results for the PleuraFlow System Anaheim, CA – November 15, 2016. ClearFlow, Inc., a medical device company based in Anaheim, California has announced the publication of positive results in a clinical trial evaluating the PleuraFlow® Active Clearance Technology® System. Data indicating a marked reduction in Retained Blood Syndrome (RBS) among patients recovering from implantation of left ventricular assist devices (LVAD) was published in the November/December 2016 edition of the American Society of Artificial Internal Organs (ASAIO) Journal (Vol. 62, Issue 66, p. 704-709). Data from the peer-reviewed paper, titled “Active Clearance of Chest Tubes Reduces Re-exploration for Bleeding After Ventricular Assist Device Implantation”

The post Reduction in Bleeding Complications After LVAD Implantation appeared first on ClearFlow.

New Study Reveals that All Patients May be at Risk for Retained Blood after Heart Surgery

January 31, 2017, 2:21 pm

≫ Next: Frost & Sullivan New Product Innovation Award for PleuraFlow Technology

≪ Previous: Reduction in Bleeding Complications After LVAD Implantation

$

0

0

— ClearFlow Executives Comment on Need for New Protocols —  Anaheim, CA – January 31, 2017—Clinical study results presented at the Society of Critical Care Medicine (SCCM) 46th Annual Critical Care Congress in Honolulu last week suggest that all heart surgery patients are at risk for Retained Blood Syndrome, not just high-risk patients, as previously assumed. All patients having heart surgery are required to have drainage catheters to remove shed blood from around the heart and lungs in the early hours of recovery following surgery.  Evidence suggests that these drainage catheters, or chest tubes, have a high failure rate due to clogging, leading to what is known as Retained Blood

The post New Study Reveals that All Patients May be at Risk for Retained Blood after Heart Surgery appeared first on ClearFlow.